Harue Igarashi

The use of biomarkers has become important for efficient drug development. Biomarkers that are essential in the use of specific drugs for patient stratification, and dose finding are used as in vitro companion diagnostics: The assessment has already been described in Japan in the Notification [1].

Since the first Japan Bioanalysis Forum (JBF) Symposium in 2011, which was the first-ever scientific meeting focused on regulated bioanalysis in Japan, the JBF continuously offers a room, for discussing bioanalytical matters/questions from Japanese scientists. The symposium celebrated its 10th anniversary recently, in February 2019. During these years, the scope of drug discovery and development has drastically changed.

All authors are members of the steering committee of the Japan Bioanalysis Forum (JBF SC) – who interviewed for the 10th anniversary issue of Bioanalysis – five members of the JBF SC to look back at the JBF's history and discuss their future expectations.